Skip to content Skip to footer
Subscribe Now
NEWS

Biogen Collaborates with Alloy Therapeutics to Advance Antisense Therapeutics

Shots: Alloy Therapeutics has entered into a collaboration & license agreement with Biogen to advance antisense therapeutics against multiple undisclosed targets using Alloy’s AntiClastic ASO Platform As per the deal, Alloy will receive an upfront payment, along with additional milestone payments & tiered royalties on any products resulting from the collaboration The AntiClastic ASO platform…
April 7, 2026

Read more

NEWS

Biocytogen and Sihuan Pharmaceutical Partner to Discover Novel Therapeutics in Multiple Indications

Shots: Biocytogen has partnered with Sihuan Pharmaceutical to discover innovative therapies across multiple areas, incl. weight loss As per the deal, Biocytogen and Sihuan will combine Biocytogen’s fully human antibody discovery platform with Sihuan’s development, manufacturing, & commercialization capabilities In this collaboration, Biocytogen will leverage its integrated platforms, incl. target-humanized mouse models, in vivo efficacy…
April 2, 2026

Read more

NEWS

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Shots: Infinimmune has partnered with Merck to discover & develop antibody candidates against multiple undisclosed targets selected by Merck using Infinimmune’s human-first antibody discovery platform As per the deal, Infinimmune will use its Anthrobody discovery platform & Glimpse antibody language model to discover & optimize antibodies from human immune repertoires, enabling large-scale B-cell screening to…
April 1, 2026

Read more

NEWS

Insilico Medicine and Eli Lilly Sign ~$2.75B Multi-Program AI-Driven Drug Discovery Collaboration

Shots: Insilico has entered into a drug discovery collaboration with Eli Lilly to accelerate the discovery & development of novel therapeutics across multiple therapeutic areas using Insilico’s Pharma.AI As per the deal, Lilly will gain exclusive global rights to develop, manufacture & commercialize Insilico’s preclinical oral candidates for select indications. Also, both will collaborate on…
March 30, 2026

Read more

NEWS

Insilico Medicine Expands AI-Driven CNS Collaboration with Tenacia in a ~$94.75M Deal

Shots: Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven R&D collaboration to develop an additional CNS candidate with defined properties, advancing it to the preclinical candidate stage for neurological disorders The initial collaboration, launched in Mar 2025, combined Insilico’s Pharma.AI platform with Tenacia’s CNS expertise to develop BBB-permeable small-molecule inhibitors, with the program progressing…
March 27, 2026

Read more

NEWS

Biogen and Alteogen Partner for ALT-B4 to Advance Subcutaneous Formulations of Biologics

Shots: Alteogen has granted Biogen exclusive rights to ALT-B4 (berahyaluronidase alfa) to develop & commercialize SC formulations of two biologics, with an option for Biogen to develop a third product As per the deal, Alteogen will receive $20M upfront, $10M upon initiation of second product development, along with ~$549M in development, regulatory, & sales milestones…
March 26, 2026

Read more

NEWS

Quotient Therapeutics & Merck Enter ~$2.2B Partnership to Discover Novel Drug Targets in IBD

Shots: Quotient has entered into a multi-year research collaboration agreement with Merck to discover novel drug targets in inflammatory bowel disease leveraging Quotient’s somatic genomics platform tech Through its somatic genomics platform, Quotient analyzes patient tissue to identify disease-causing or protective mutations, generating insights that inform novel therapeutic strategies across multiple conditions, including IBD As…
March 24, 2026

Read more

NEWS

Gilead to Acquire Ouro Medicine for ~$2.1B

Shots: Gilead to acquire Ouro for a total of $1,675M in upfront cash & up to $500M in contingent milestone payments. Acquisition will add Ouro’s P-I/II asset OM336 (gamgertamig) to Gilead’s inflammation portfolio, with registrational studies to begin in 2027 Also, Gilead is in advanced discussions with Galapagos for a potential R&D collaboration on the…
March 24, 2026

Read more

NEWS

Voro Therapeutics Collaborates with Daiichi Sankyo to Develop Tumor-Activated ADCs

Shots: Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo via its Daiichi Sankyo Research Institute, San Diego to develop tumor-activated biologics using the PrimeBody platform The collaboration will focus on generating masked ADCs designed for tumor-selective activation, using proprietary masking domains & protease-cleavable linkers to improve therapeutic index  Voro will design &…
March 18, 2026

Read more

Load more